Item 1. Financial Statements
103K characters. Original on sec.gov ·
Item 1. Financial Statements
KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
| Three Months Ended September 30 | Nine Months Ended September 30 | |||||||||||||||||||||||||
| (In millions, except per share amounts) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| Net Sales | $ | 4,134 | $ | 4,150 | $ | 12,486 | $ | 12,367 | ||||||||||||||||||
| Cost of products sold | 2,693 | 2,657 | 7,908 | 7,909 | ||||||||||||||||||||||
| Gross Profit | 1,441 | 1,493 | 4,578 | 4,458 | ||||||||||||||||||||||
| Marketing, research and general expenses | 912 | 855 | 2,836 | 2,573 | ||||||||||||||||||||||
| Other (income) and expense, net | 13 | 17 | (160) | 41 | ||||||||||||||||||||||
| Operating Profit | 516 | 621 | 1,902 | 1,844 | ||||||||||||||||||||||
| Nonoperating expense | (13) | (16) | (40) | (50) | ||||||||||||||||||||||
| Interest income | 16 | 6 | 25 | 18 | ||||||||||||||||||||||
| Interest expense | (48) | (65) | (159) | (196) | ||||||||||||||||||||||
| Income from Continuing Operations Before Income Taxes and Equity Interests | 471 | 546 | 1,728 | 1,616 | ||||||||||||||||||||||
| Provision for income taxes | (95) | (248) | (476) | (495) | ||||||||||||||||||||||
| Income from Continuing Operations Before Equity Interests | 376 | 298 | 1,252 | 1,121 | ||||||||||||||||||||||
| Share of net income of equity companies | 29 | 46 | 137 | 137 | ||||||||||||||||||||||
| Income from Continuing Operations | 405 | 344 | 1,389 | 1,258 | ||||||||||||||||||||||
| Income from Discontinued Operations, Net of Income Taxes | 1,395 | 110 | 1,436 | 281 | ||||||||||||||||||||||
| Net Income | 1,800 | 454 | 2,825 | 1,539 | ||||||||||||||||||||||
| Net income attributable to noncontrolling interests | (7) | (8) | (22) | (17) | ||||||||||||||||||||||
| Net Income Attributable to Kimberly-Clark Corporation | $ | 1,793 | $ | 446 | $ | 2,803 | $ | 1,522 | ||||||||||||||||||
| Per Share Basis | ||||||||||||||||||||||||||
| Net Income Attributable to Kimberly-Clark Corporation | ||||||||||||||||||||||||||
| Basic: | ||||||||||||||||||||||||||
| Continuing operations | $ | 1.20 | $ | 1.01 | $ | 4.11 | $ | 3.74 | ||||||||||||||||||
| Discontinued operations | 4.19 | 0.33 | 4.33 | 0.85 | ||||||||||||||||||||||
| Basic Earnings per Share | $ | 5.39 | $ | 1.34 | $ | 8.44 | $ | 4.59 | ||||||||||||||||||
| Diluted: | ||||||||||||||||||||||||||
| Continuing operations | $ | 1.19 | $ | 1.01 | $ | 4.10 | $ | 3.73 | ||||||||||||||||||
| Discontinued operations | 4.18 | 0.33 | 4.31 | 0.84 | ||||||||||||||||||||||
| Diluted Earnings per Share | $ | 5.37 | $ | 1.34 | $ | 8.41 | $ | 4.57 |
See Notes to the Unaudited Interim Condensed Consolidated Financial Statements.
KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
| Three Months Ended September 30 | Nine Months Ended September 30 | |||||||||||||||||||||||||
| (In millions) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| Net Income | $ | 1,800 | $ | 454 | $ | 2,825 | $ | 1,539 | ||||||||||||||||||
| Other Comprehensive Income (Loss), Net of Tax | ||||||||||||||||||||||||||
| Unrealized currency translation adjustments | (330) | (11) | (338) | 361 | ||||||||||||||||||||||
| Employee postretirement benefits | 7 | 13 | 48 | 4 | ||||||||||||||||||||||
| Cash flow hedges | 112 | 5 | 133 | (94) | ||||||||||||||||||||||
| Total Other Comprehensive Income (Loss), Net of Tax | (211) | 7 | (157) | 271 | ||||||||||||||||||||||
| Comprehensive Income | 1,589 | 461 | 2,668 | 1,810 | ||||||||||||||||||||||
| Comprehensive income attributable to noncontrolling interests | (17) | (5) | (28) | (20) | ||||||||||||||||||||||
| Comprehensive Income Attributable to Kimberly-Clark Corporation | $ | 1,572 | $ | 456 | $ | 2,640 | $ | 1,790 |
See Notes to the Unaudited Interim Condensed Consolidated Financial Statements.
KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| (In millions, except par value) | September 30, 2026 | December 31, 2025 | ||||||||||||
| ASSETS | ||||||||||||||
| Current Assets | ||||||||||||||
| Cash and cash equivalents | $ | 1,874 | $ | 688 | ||||||||||
| Accounts receivable, net | 1,975 | 1,892 | ||||||||||||
| Inventories | 1,579 | 1,475 | ||||||||||||
| Other current assets | 517 | 535 | ||||||||||||
| Current assets of discontinued operations | — | 720 | ||||||||||||
| Total Current Assets | 5,945 | 5,310 | ||||||||||||
| Property, Plant and Equipment, Net | 7,067 | 6,775 | ||||||||||||
| Investments in Equity Companies | 1,592 | 330 | ||||||||||||
| Goodwill | 1,828 | 1,839 | ||||||||||||
| Other Intangible Assets, Net | 72 | 77 | ||||||||||||
| Other Assets | 1,215 | 1,062 | ||||||||||||
| Non-current Assets of Discontinued Operations | — | 1,705 | ||||||||||||
| TOTAL ASSETS | $ | 17,719 | $ | 17,098 | ||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||
| Current Liabilities | ||||||||||||||
| Debt payable within one year | $ | 621 | $ | 694 | ||||||||||
| Trade accounts payable | 3,417 | 3,388 | ||||||||||||
| Accrued expenses and other current liabilities | 2,205 | 1,888 | ||||||||||||
| Dividends payable | 423 | 415 | ||||||||||||
| Current liabilities of discontinued operations | — | 740 | ||||||||||||
| Total Current Liabilities | 6,666 | 7,125 | ||||||||||||
| Long-Term Debt | 5,870 | 6,474 | ||||||||||||
| Non-current Employee Benefits | 556 | 605 | ||||||||||||
| Deferred Income Taxes | 420 | 445 | ||||||||||||
| Other Liabilities | 1,111 | 646 | ||||||||||||
| Non-current Liabilities of Discontinued Operations | — | 151 | ||||||||||||
| Redeemable Preferred Securities of Subsidiaries | 22 | 22 | ||||||||||||
| Stockholders' Equity | ||||||||||||||
| Kimberly-Clark Corporation | ||||||||||||||
| Preferred stock - no par value - authorized 20.0 million shares, none issued | — | — | ||||||||||||
| Common stock - $1.25 par value - authorized 1,200.0 million shares; issued 378.6 million shares as of September 30, 2026 and December 31, 2025 | 473 | 473 | ||||||||||||
| Additional paid-in capital | 820 | 849 | ||||||||||||
| Common stock held in treasury, at cost - 46.0 and 46.7 million shares as of September 30, 2026 and December 31, 2025, respectively | (5,882) | (5,987) | ||||||||||||
| Retained earnings | 11,128 | 9,611 | ||||||||||||
| Accumulated other comprehensive income (loss) | (3,607) | (3,444) | ||||||||||||
| Total Kimberly-Clark Corporation Stockholders' Equity | 2,932 | 1,502 | ||||||||||||
| Noncontrolling Interests | 142 | 128 | ||||||||||||
| Total Stockholders' Equity | 3,074 | 1,630 | ||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 17,719 | $ | 17,098 |
See Notes to the Unaudited Interim Condensed Consolidated Financial Statements.
KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited)
| Three Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (In millions, except per share amounts. Shares in thousands) | Common Stock Issued | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Non-controlling Interests | Total Stockholders' Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance as of June 30, 2026 | 378,597 | $ | 473 | $ | 788 | 46,037 | $ | (5,890) | $ | 9,765 | $ | (3,386) | $ | 124 | $ | 1,874 | ||||||||||||||||||||||||||||||||||||||||
| Net income in stockholders' equity(a) | — | — | — | — | — | 1,793 | — | 8 | 1,801 | |||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax(a) | — | — | — | — | — | — | (221) | 10 | (211) | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based awards exercised or vested | — | — | (11) | (52) | 8 | — | — | — | (3) | |||||||||||||||||||||||||||||||||||||||||||||||
| Recognition of stock-based compensation | — | — | 41 | — | — | — | — | — | 41 | |||||||||||||||||||||||||||||||||||||||||||||||
| Dividends declared ($1.28 per share) | — | — | — | — | — | (425) | — | (1) | (426) | |||||||||||||||||||||||||||||||||||||||||||||||
| Other | — | — | 2 | — | — | (5) | — | 1 | (2) | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2026 | 378,597 | $ | 473 | $ | 820 | 45,985 | $ | (5,882) | $ | 11,128 | $ | (3,607) | $ | 142 | $ | 3,074 |
| Nine Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (In millions, except per share amounts. Shares in thousands) | Common Stock Issued | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Non-controlling Interests | Total Stockholders' Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance as of December 31, 2025 | 378,597 | $ | 473 | $ | 849 | 46,699 | $ | (5,987) | $ | 9,611 | $ | (3,444) | $ | 128 | $ | 1,630 | ||||||||||||||||||||||||||||||||||||||||
| Net income in stockholders' equity(a) | — | — | — | — | — | 2,803 | — | 24 | 2,827 | |||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax(a) | — | — | — | — | — | — | (163) | 4 | (159) | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based awards exercised or vested | — | — | (138) | (714) | 104 | — | — | — | (34) | |||||||||||||||||||||||||||||||||||||||||||||||
| Recognition of stock-based compensation | — | — | 103 | — | — | — | — | — | 103 | |||||||||||||||||||||||||||||||||||||||||||||||
| Dividends declared ($3.84 per share) | — | — | — | — | — | (1,276) | — | (15) | (1,291) | |||||||||||||||||||||||||||||||||||||||||||||||
| Other | — | — | 6 | — | 1 | (10) | — | 1 | (2) | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2026 | 378,597 | $ | 473 | $ | 820 | 45,985 | $ | (5,882) | $ | 11,128 | $ | (3,607) | $ | 142 | $ | 3,074 |
(a) Excludes redeemable interests' share.
KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited)
| Three Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (In millions, except per share amounts. Shares in thousands) | Common Stock Issued | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Non-controlling Interests | Total Stockholders' Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance as of June 30, 2025 | 378,597 | $ | 473 | $ | 798 | 46,682 | $ | (5,986) | $ | 9,494 | $ | (3,508) | $ | 132 | $ | 1,403 | ||||||||||||||||||||||||||||||||||||||||
| Net income in stockholders' equity(a) | — | — | — | — | — | 446 | — | 7 | 453 | |||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax(a) | — | — | — | — | — | — | 10 | (3) | 7 | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based awards exercised or vested | — | — | (12) | (83) | 11 | — | — | — | (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Repurchases of common stock | — | — | — | 140 | (17) | — | — | — | (17) | |||||||||||||||||||||||||||||||||||||||||||||||
| Recognition of stock-based compensation | — | — | 41 | — | — | — | — | — | 41 | |||||||||||||||||||||||||||||||||||||||||||||||
| Dividends declared ($1.26 per share) | — | — | — | — | — | (418) | — | — | (418) | |||||||||||||||||||||||||||||||||||||||||||||||
| Other | — | — | 2 | — | — | (2) | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2025 | 378,597 | $ | 473 | $ | 829 | 46,739 | $ | (5,992) | $ | 9,520 | $ | (3,498) | $ | 136 | $ | 1,468 |
| Nine Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (In millions, except per share amounts. Shares in thousands) | Common Stock Issued | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Non-controlling Interests | Total Stockholders' Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance as of December 31, 2024 | 378,597 | $ | 473 | $ | 862 | 46,798 | $ | (5,986) | $ | 9,257 | $ | (3,766) | $ | 135 | $ | 975 | ||||||||||||||||||||||||||||||||||||||||
| Net income in stockholders' equity(a) | — | — | — | — | — | 1,522 | — | 16 | 1,538 | |||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax(a) | — | — | — | — | — | — | 268 | 3 | 271 | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based awards exercised or vested | — | — | (153) | (1,114) | 141 | — | — | — | (12) | |||||||||||||||||||||||||||||||||||||||||||||||
| Repurchases of common stock | — | — | — | 1,055 | (140) | — | — | — | (140) | |||||||||||||||||||||||||||||||||||||||||||||||
| Recognition of stock-based compensation | — | — | 111 | — | — | — | — | — | 111 | |||||||||||||||||||||||||||||||||||||||||||||||
| Dividends declared ($3.78 per share) | — | — | — | — | — | (1,255) | — | (17) | (1,272) | |||||||||||||||||||||||||||||||||||||||||||||||
| Other | — | — | 9 | — | (7) | (4) | — | (1) | (3) | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2025 | 378,597 | $ | 473 | $ | 829 | 46,739 | $ | (5,992) | $ | 9,520 | $ | (3,498) | $ | 136 | $ | 1,468 |
(a) Excludes redeemable interests' share.
See Notes to the Unaudited Interim Condensed Consolidated Financial Statements.
KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| Nine Months Ended September 30 | |||||||||||||||||
| (In millions) | 2026 | 2025 | |||||||||||||||
| Operating Activities | |||||||||||||||||
| Net income | $ | 2,825 | $ | 1,539 | |||||||||||||
| Depreciation and amortization | 544 | 616 | |||||||||||||||
| Stock-based compensation | 106 | 115 | |||||||||||||||
| Deferred income taxes | (177) | 204 | |||||||||||||||
| Net (gains) losses on asset and business dispositions | (1,497) | 42 | |||||||||||||||
| Equity companies' earnings (in excess of) less than dividends paid | (48) | (56) | |||||||||||||||
| Operating working capital | 265 | (679) | |||||||||||||||
| Proceeds from long-term license agreement | 444 | — | |||||||||||||||
| Postretirement benefits | 1 | 17 | |||||||||||||||
| Other | (55) | 7 | |||||||||||||||
| Cash Provided by Operations | 2,408 | 1,805 | |||||||||||||||
| Investing Activities | |||||||||||||||||
| Capital spending | (1,039) | (741) | |||||||||||||||
| Proceeds from asset and business dispositions | 445 | 12 | |||||||||||||||
| Investments in time deposits | (210) | (375) | |||||||||||||||
| Maturities of time deposits | 223 | 416 | |||||||||||||||
| Other | 29 | 38 | |||||||||||||||
| Cash Used for Investing | (552) | (650) | |||||||||||||||
| Financing Activities | |||||||||||||||||
| Cash dividends paid | (1,268) | (1,242) | |||||||||||||||
| Change in short-term debt | (274) | 414 | |||||||||||||||
| Debt proceeds | 1,329 | — | |||||||||||||||
| Debt repayments | (400) | (550) | |||||||||||||||
| Proceeds from exercise of stock options | — | 40 | |||||||||||||||
| Repurchases of common stock | — | (140) | |||||||||||||||
| Cash dividends paid to noncontrolling interests | (15) | (18) | |||||||||||||||
| Other | (45) | (75) | |||||||||||||||
| Cash Used for Financing | (673) | (1,571) | |||||||||||||||
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (10) | 29 | |||||||||||||||
| Change in Cash and Cash Equivalents | 1,173 | (387) | |||||||||||||||
| Cash and cash equivalents from continuing operations - beginning of period | 688 | 1,010 | |||||||||||||||
| Cash and cash equivalents from discontinued operations - beginning of period(a) | 13 | 11 | |||||||||||||||
| Cash and Cash Equivalents - Beginning of Period | 701 | 1,021 | |||||||||||||||
| Cash and cash equivalents from continuing operations - end of period | 1,874 | 617 | |||||||||||||||
| Cash and cash equivalents from discontinued operations - end of period(a) | — | 17 | |||||||||||||||
| Cash and Cash Equivalents - End of Period | $ | 1,874 | $ | 634 |
(a) Included in Current assets of discontinued operations for periods prior to the completion of the IFP Transaction.
See Notes to the Unaudited Interim Condensed Consolidated Financial Statements.
KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Note 1. Accounting Policies
Basis of Presentation
The accompanying Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair statement of the results for the periods presented have been reflected. Amounts are reported in millions of dollars, except per share amounts, unless otherwise noted.
For further information, refer to the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2025. The terms "Corporation," "Company," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries.
International Family Care and Professional ("IFP") Transaction
On July 1, 2026, all consultation requirements and customary closing conditions set forth in the Equity and Asset Purchase Agreement (the "Purchase Agreement") with Suzano International Holding B.V. ("Buyer"), a wholly-owned subsidiary of Suzano S.A. ("Suzano"), were satisfied and the transaction was completed. Pursuant to the Purchase Agreement, we contributed substantially all of the assets and liabilities of the Company's former International Family Care and Professional ("IFP") segment (the "IFP Business") to FamPro Tissue Holdings B.V. (formerly known as Kimberly-Clark IFP NewCo B.V.), a newly formed joint venture (the "Arbex Joint Venture"). At closing, Buyer acquired a 51% interest in the Arbex Joint Venture for a cash purchase price of approximately $1.3 billion, subject to certain post-closing adjustments, and we retained a 49% equity interest (the "IFP Transaction").
In accordance with ASC 205, Presentation of Financial Statements, we determined the IFP Transaction represented a strategic shift that had a major effect on our operations and financial results. Accordingly, the results of the IFP Business through the closing date are reported as discontinued operations in the accompanying Condensed Consolidated Statements of Income and have been excluded from both continuing operations and segment results for all periods presented. Further, assets and liabilities of the IFP Business were classified as discontinued operations in the accompanying Condensed Consolidated Balance Sheets as of December 31, 2025. The Condensed Consolidated Statements of Comprehensive Income, Stockholders' Equity and Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. Unless otherwise noted, amounts and disclosures in the Notes to the Unaudited Interim Condensed Consolidated Financial Statements reflect only Kimberly-Clark's continuing operations. See Note 3 for additional details.
Highly Inflationary Accounting
GAAP requires the use of highly inflationary accounting for countries whose cumulative three-year inflation exceeds 100%. Under highly inflationary accounting, the countries’ functional currency becomes the U.S. dollar, and its income statement and balance sheet are measured in U.S. dollars using both current and historical rates of exchange.
As of July 1, 2018, we adopted highly inflationary accounting for our subsidiaries in Argentina ("K-C Argentina"). The effect of changes in exchange rates on peso-denominated monetary assets and liabilities has been reflected in earnings in Other (income) and expense, net. As of September 30, 2026, K-C Argentina had an immaterial net peso monetary position. Net sales of K-C Argentina were approximately 1% of our net sales for the three and nine months ended September 30, 2026 and 2025.
As of April 1, 2022, we adopted highly inflationary accounting for our subsidiary in Türkiye ("K-C Türkiye"). The effect of changes in exchange rates on lira-denominated monetary assets and liabilities has been reflected in earnings in Other (income) and expense, net. As of September 30, 2026, K-C Türkiye had an immaterial net lira monetary position. Net sales of K-C Türkiye were less than 1% of our net sales for the three and nine months ended September 30, 2026 and 2025.
Recently Issued Accounting Standards
In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Topic 220). The new guidance requires disclosure in the notes to the financial statements of disaggregated information about specific expense categories underlying certain income statement expense line items. The amendments in this ASU are effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments should be applied on a prospective basis with retrospective application permitted. We are currently evaluating the impact of this update on our consolidated financial statements and related disclosures.
In September 2025, the FASB issued ASU No. 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Topic 350) to modernize the accounting guidance for internal-use software costs. The new guidance eliminates software development stages and clarifies when to begin capitalizing eligible software costs. The amendments in this ASU are effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted. The amendments can be applied on a prospective basis, a modified basis for in-process projects or a retrospective basis. We are currently evaluating the impact of this update on our consolidated financial statements and related disclosures.
In December 2025, the FASB issued ASU No. 2025-10, Government Grants (Topic 832) to establish guidance on the recognition, measurement and presentation of government grants received by business entities*.* The amendments in this ASU are effective for fiscal years beginning after December 15, 2028, and interim periods within those fiscal years, with early adoption permitted. The amendments can be applied on a modified prospective basis, a modified retrospective basis or a retrospective basis. We are currently evaluating the impact of this update on our consolidated financial statements and related disclosures.
Note 2. 2024 Transformation Initiative
On March 27, 2024, we announced the 2024 Transformation Initiative intended to improve our focus on growth and reduce our structural cost base by realigning our internal operating and management structure to streamline our global supply chain and improve the efficiency of our corporate and regional overhead cost structures. The transformation is expected to impact our organization in all major geographies, and workforce reductions are expected to be in the range of 4% to 5%. Certain actions under the 2024 Transformation Initiative are being finalized for implementation, and accounting for such actions will commence when the actions are authorized for execution.
During the second quarter of 2026, our Board of Directors approved an extension of the 2024 Transformation Initiative through the end of 2028. Total pre-tax costs are anticipated to be approximately $1.5 billion, with cash costs expected to be approximately 60% of that amount, primarily related to workforce reductions and other program costs. Expected non-cash charges are primarily related to incremental depreciation and asset write-offs, including losses associated with the expected exit of certain markets. Through September 30, 2026, cumulative pre-tax charges for the 2024 Transformation Initiative were $968 ($750 after-tax).
The following charges were incurred in connection with the 2024 Transformation Initiative:
| Three Months Ended September 30 | Nine Months Ended September 30 | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Cost of products sold: | ||||||||||||||||||||||||||
| Charges for workforce reductions | $ | — | $ | 3 | $ | 3 | $ | 17 | ||||||||||||||||||
| Asset write-offs | — | 7 | 20 | 27 | ||||||||||||||||||||||
| Incremental depreciation | 20 | 15 | 51 | 104 | ||||||||||||||||||||||
| Other exit costs | 9 | 9 | 19 | 21 | ||||||||||||||||||||||
| Total | 29 | 34 | 93 | 169 | ||||||||||||||||||||||
| Marketing, research and general expenses: | ||||||||||||||||||||||||||
| Charges for workforce reductions | 3 | 1 | 18 | 16 | ||||||||||||||||||||||
| Other exit costs | 21 | 27 | 69 | 73 | ||||||||||||||||||||||
| Total | 24 | 28 | 87 | 89 | ||||||||||||||||||||||
| Other (income) and expense, net(a) | 2 | — | (20) | — | ||||||||||||||||||||||
| Nonoperating expense | — | — | — | 3 | ||||||||||||||||||||||
| Total charges**(b)** | 55 | 62 | 160 | 261 | ||||||||||||||||||||||
| Provision for income taxes | (11) | (12) | (44) | (39) | ||||||||||||||||||||||
| Net charges | 44 | 50 | 116 | 222 | ||||||||||||||||||||||
| Net charges related to noncontrolling interests | (1) | (3) | (2) | (7) | ||||||||||||||||||||||
| Net charges attributable to Kimberly-Clark Corporation | $ | 43 | $ | 47 | $ | 114 | $ | 215 |
(a)Other (income) and expense, net includes gains from the sale of manufacturing facilities and associated real estate as part of the 2024 Transformation Initiative.
(b)We do not include 2024 Transformation Initiative charges within our segment operating results. Total impact of these charges to the NA segment would have been $43 and $144 for the three and nine months ended September 30, 2026, respectively (IPC segment amounts were not material); $32 and $36 to the NA and IPC segments, respectively, for the three months ended September 30, 2025; and $117 and $127 to the NA and IPC segments, respectively, for the nine months ended September 30, 2025, with the residual relating to Corporate & Other. See further discussion around our segment operating results in Note 10.
The following summarizes the 2024 Transformation Initiative liabilities activity:
| Total | ||||||||
| Liabilities as of December 31, 2025 | $ | 62 | ||||||
| Charges for workforce reductions and other cash exit costs | 106 | |||||||
| Cash payments | (116) | |||||||
| Currency and other | (11) | |||||||
| Liabilities as of September 30, 2026 | $ | 41 |
2024 Transformation Initiative liabilities are recorded in Accrued expenses and other current liabilities. The charges related to the 2024 Transformation Initiative are reflected within Operating Activities of our Condensed Consolidated Statements of Cash Flows.
Note 3. Discontinued Operations
As disclosed in Note 1, on July 1, 2026, all consultation requirements and customary closing conditions set forth in the Purchase Agreement were satisfied and the IFP Transaction was completed for a cash purchase price of approximately $1.3 billion, reflecting certain closing cash, working capital, debt and other adjustments described in the Purchase Agreement, and subject to certain post-closing adjustments.
Upon closing, we recognized a pre-tax gain of approximately $1.4 billion during the third quarter of 2026, which is included in Income from Discontinued Operations, Net of Income Taxes, calculated as follows:
| Cash proceeds, gross | $ | 1,293 | ||||||
| Less: | ||||||||
| Long-term intellectual property licenses | (444) | |||||||
| Deferred obligations and other(a) | (33) | |||||||
| Cash proceeds, net | 816 | |||||||
| Fair value of retained equity interest(b) | 1,242 | |||||||
| Total purchase price | 2,058 | |||||||
| Less: | ||||||||
| Transaction costs | (49) | |||||||
| Net assets disposed(c)(d) | (875) | |||||||
| Reclassification of cumulative translation adjustment | 310 | |||||||
| Pre-tax gain | $ | 1,444 |
(a)Represents other deferred obligations determined to be separate of the divestiture, primarily relating to deferred TSA credits and post-closing accruals.
(b)Fair value of retained equity interest represents a non-cash investing activity.
(c)Immediately prior to the completion of the IFP Transaction, the Company borrowed approximately $1.3 billion under a term loan facility entered into in connection with the IFP Transaction. Upon completion of the IFP Transaction, the related obligations were transferred to the Arbex Joint Venture and became non-recourse to Kimberly-Clark.
(d)Includes approximately $407 of cash and cash equivalents.
Financial Information of Discontinued Operations
The following table presents the components of Income from Discontinued Operations, Net of Income Taxes:
| Three Months Ended September 30 | Nine Months Ended September 30 | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Net Sales | $ | — | $ | 828 | $ | 1,642 | $ | 2,416 | ||||||||||||||||||
| Cost of products sold | 5 | 579 | 1,156 | 1,733 | ||||||||||||||||||||||
| Gross Profit | (5) | 249 | 486 | 683 | ||||||||||||||||||||||
| Marketing, research and general expenses | 47 | 103 | 328 | 297 | ||||||||||||||||||||||
| Other (income) and expense, net(a) | (1,444) | — | (1,442) | 2 | ||||||||||||||||||||||
| Operating Profit | 1,392 | 146 | 1,600 | 384 | ||||||||||||||||||||||
| Nonoperating expense | — | — | — | — | ||||||||||||||||||||||
| Income from discontinued operations before income taxes | 1,392 | 146 | 1,600 | 384 | ||||||||||||||||||||||
| Provision for income taxes | 3 | (36) | (164) | (103) | ||||||||||||||||||||||
| Income from Discontinued Operations, Net of Income Taxes | $ | 1,395 | $ | 110 | $ | 1,436 | $ | 281 |
(a)Other (income) and expense, net for the three and nine months ended September 30, 2026 includes the pre-tax gain recognized upon the completion of the IFP Transaction.
As a result of the IFP Transaction, we incurred separation costs of $52 and $156 for the three and nine months ended September 30, 2026, respectively, and $17 and $50 for the three and nine months ended September 30, 2025, respectively, which are included in the reported amounts above. These costs were primarily related to external advisory, legal, accounting, contractor and other incremental costs directly related to the IFP Transaction.
The Provision for income taxes for the nine months ended September 30, 2026 includes incremental net tax charges relating to the impacts from an intercompany intellectual property transaction and reorganization activities completed in connection with the IFP Transaction.
The following table presents significant non-cash items and capital expenditures of discontinued operations:
| Three Months Ended September 30 | Nine Months Ended September 30 | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Depreciation and Amortization(a) | $ | — | $ | — | $ | — | $ | 68 | ||||||||||||||||||
| Capital Spending | — | 27 | 81 | 73 |
(a)The Company ceased depreciating and amortizing the long-lived assets of the IFP Business upon classification as discontinued operations.
The following table presents the components of assets and liabilities classified as discontinued operations:
| December 31, 2025 | ||||||||||||||
| Assets | ||||||||||||||
| Cash and cash equivalents | $ | 13 | ||||||||||||
| Accounts receivable, net | 302 | |||||||||||||
| Inventories | 383 | |||||||||||||
| Other current assets | 22 | |||||||||||||
| Current Assets of Discontinued Operations | $ | 720 | ||||||||||||
| Property, Plant and Equipment, Net | $ | 1,425 | ||||||||||||
| Goodwill | 179 | |||||||||||||
| Other Intangible Assets, Net | 7 | |||||||||||||
| Other Assets | 94 | |||||||||||||
| Non-current Assets of Discontinued Operations | $ | 1,705 | ||||||||||||
| Liabilities | ||||||||||||||
| Debt payable within one year | $ | 4 | ||||||||||||
| Trade accounts payable | 500 | |||||||||||||
| Accrued expenses and other current liabilities | 236 | |||||||||||||
| Current Liabilities of Discontinued Operations | $ | 740 | ||||||||||||
| Long-Term Debt | $ | 18 | ||||||||||||
| Non-current Employee Benefits | 18 | |||||||||||||
| Deferred Income Taxes | 32 | |||||||||||||
| Other Liabilities | 83 | |||||||||||||
| Non-current Liabilities of Discontinued Operations | $ | 151 |
Equity Method Investment
As part of the IFP Transaction, we retained a 49% non-controlling equity interest in the Arbex Joint Venture, which had an initial fair value of approximately $1.2 billion and is accounted for under the equity method of accounting. For the three months ended September 30, 2026, the Arbex Joint Venture's pre-tax loss was $54, and our share of the Arbex Joint Venture's net loss was $20, which is included in Share of net income of equity companies in the Condensed Consolidated Statements of Income.
Joint Venture Agreement and Ancillary Agreements
Upon the completion of the IFP Transaction, K-C, Buyer and the Arbex Joint Venture entered into a joint venture agreement (the "JVA"), which set forth provisions relating to, among other things, the governance of the Arbex Joint Venture following closing, transfer restrictions with respect to the parties’ interests in the Arbex Joint Venture, and the option of Buyer to purchase K-C's equity interests in the Arbex Joint Venture. We also entered into certain ancillary agreements including for the use of certain intellectual property, transition services agreements (the "TSA") and transitional supply arrangements (the "Supply Agreements"). Transactions associated with these ancillary agreements are reported in continuing operations, as discussed further below.
We granted long-term licenses to the Arbex Joint Venture for the use of certain of K-C's global brands, patents, and know-how in manufacturing for a period of up to 30 years (the "IFP Licensed IP Agreement"). Of the cash proceeds received from the IFP Transaction, approximately $444 was attributed to the IFP Licensed IP Agreement based on its estimated fair value. This deferred income will be recognized in Net sales over the contractual term of the agreement. For the three months ended September 30, 2026, license income related to the IFP Licensed IP Agreement was not material.
Pursuant to the TSA, K-C will provide certain services to the Arbex Joint Venture, on an interim, transitional basis from and after the closing for an initial duration of 18 months, with certain extension rights provided therein. The remuneration to be paid for such services is generally intended to allow K-C to recover all of its costs and expenses of providing such services. For the three months ended September 30, 2026, we recognized $23 of cost reimbursements related to services provided under the TSA, which are included in Marketing, research and general expense as a direct offset to the costs incurred related to providing these services.
Pursuant to the Supply Agreements, K-C will manufacture and supply certain products to the Arbex Joint Venture and, similarly, the Arbex Joint Venture will manufacture and supply certain products to K-C for a period of up to 36 months following the closing with certain extension rights provided therein. For the three months ended September 30, 2026, sales to the Arbex Joint Venture under the Supply Agreements resulted in Net sales and Cost of products sold of $23. K-C purchases from the Arbex Joint Venture were not material. Prior to the completion of the IFP Transaction, these transactions were eliminated in the consolidated financial statements as intercompany transactions.
Amounts due from the Arbex Joint Venture and amounts due to the Arbex Joint Venture under the agreements described above were $41 and $17, respectively, as of September 30, 2026.
Note 4**. Acquisitions**
Acquisition of Kenvue, Inc.
On November 2, 2025, we entered into an Agreement and Plan of Merger (the "Merger Agreement") to acquire the outstanding equity interests of Kenvue, Inc. ("Kenvue"), a global consumer health leader, for stock and cash consideration (the "Kenvue Acquisition"). Under the terms of the Merger Agreement, which was unanimously approved by the Boards of Directors of each of Kimberly-Clark and Kenvue, each share of Kenvue common stock, par value $0.01 per share, issued and outstanding at the close of the Kenvue Acquisition (subject to certain provisions of the Merger Agreement) will be converted into the right to receive (i) 0.14625 shares of Kimberly-Clark common stock, par value $1.25 per share (the "Stock Consideration"), plus (ii) $3.50 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). Furthermore, each Kenvue equity award outstanding immediately prior to the close of the Kenvue Acquisition will be converted into an equivalent K-C equity award, subject to and in accordance with the provisions of the Merger Agreement.
On January 29, 2026, Kimberly-Clark and Kenvue each held a special meeting of their respective stockholders. During the respective meetings, Kimberly-Clark stockholders approved by requisite vote the issuance of Kimberly-Clark common stock as consideration to holders of Kenvue common stock, and Kenvue stockholders adopted by the requisite vote the Merger Agreement. Additionally, the waiting period applicable to the Kenvue Acquisition under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired on February 4, 2026.
On November 2, 2026, we completed the Kenvue Acquisition for Cash Consideration of approximately $6.7 billion. In respect of the Kenvue common stock issued and outstanding immediately prior to the effective time of the Kenvue Acquisition, we have delivered or caused to be delivered approximately 281.1 million shares of K-C common stock to Kenvue shareholders. The Cash Consideration was funded through a combination of cash on hand, proceeds from new debt issuance, and borrowings under our commercial paper program. See Note 12 for further information.
During the three and nine months ended September 30, 2026, we incurred $106 and $263, respectively, of acquisition-related costs in connection with the Kenvue Acquisition, which are included in Marketing, research and general expenses. As of September 30, 2026 and December 31, 2025, Other current assets included deferred share issuance costs of $6. Upon completion of the Kenvue Acquisition, as discussed above, these costs were recognized in Additional paid-in capital.
Note 5. Fair Value Information
The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are:
Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities.
Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly.
Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable.
A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
During the nine months ended September 30, 2026 and for the full year 2025, there were no significant transfers to or from level 3 fair value determinations.
Derivative assets and liabilities are measured on a recurring basis at fair value. As of September 30, 2026 and December 31, 2025, derivative assets were $235 and $81, respectively, and derivative liabilities were $215 and $191, respectively. The fair values of derivatives used to manage interest rate risk and commodity price risk are based on the Secured Overnight Financing Rate ("SOFR") and interest rate swap curves and on commodity price quotations, respectively. The fair values of hedging instruments used to manage foreign currency risk are based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates. Measurement of our derivative assets and liabilities is considered a level 2 measurement. See Note 9 for additional information on our use of derivative instruments.
Redeemable preferred securities of subsidiaries are measured on a recurring basis at their estimated redemption values, which approximate fair value. As of September 30, 2026 and December 31, 2025, the securities were valued at $22. The securities are not traded in active markets, and their measurement is considered a level 3 measurement.
Company-owned life insurance ("COLI") assets are measured on a recurring basis at fair value. COLI assets were $70 and $71 as of September 30, 2026 and December 31, 2025, respectively. The COLI policies are a source of funding primarily for our nonqualified employee benefits and are included in Other Assets in the Condensed Consolidated Balance Sheets. The COLI policies are measured at fair value using the net asset value per share practical expedient, and therefore, are not classified in the fair value hierarchy.
The following table includes the fair value of our financial instruments for which disclosure of fair value is required:
| Fair Value Hierarchy Level | Carrying Amount | Estimated Fair Value | Carrying Amount | Estimated Fair Value | ||||||||||||||||||||||||||||
| September 30, 2026 | December 31, 2025 | |||||||||||||||||||||||||||||||
| Assets | ||||||||||||||||||||||||||||||||
| Cash and cash equivalents(a) | 1 | $ | 1,874 | $ | 1,874 | $ | 688 | $ | 688 | |||||||||||||||||||||||
| Time deposits(b) | 1 | 87 | 87 | 94 | 94 | |||||||||||||||||||||||||||
| Liabilities | ||||||||||||||||||||||||||||||||
| Short-term debt(c) | 2 | 10 | 10 | 282 | 282 | |||||||||||||||||||||||||||
| Long-term debt(d) | 2 | 6,481 | 5,755 | 6,886 | 6,491 |
(a)Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
(b)Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in Other current assets or Other Assets in the Condensed Consolidated Balance Sheets, as appropriate. Time deposits are recorded at cost, which approximates fair value.
(c)Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
(d)Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
Note 6. Income Taxes
On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the U.S. As a result, during the three months ended September 30, 2025, we recorded incremental tax charges of approximately $130 primarily relating to a valuation allowance on U.S. foreign tax credits generated in 2025 and prior. Of these total charges, approximately $96 was associated with the realizability of U.S. foreign tax credits generated prior to 2025.
The effective tax rate for the three months ended September 30, 2026 and 2025 was 20.2% and 45.4%, respectively, and 27.5% and 30.6% for the nine months ended September 30, 2026 and 2025, respectively. The decreases relative to the prior periods were primarily driven by the valuation allowance charges relating to the enactment of OBBBA discussed above.
See Note 14, Income Taxes, to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2025 for further information regarding OBBBA.
Note 7. Earnings Per Share
Basic and diluted earnings per share ("EPS") were calculated as follows:
| Three Months Ended September 30 | Nine Months Ended September 30 | |||||||||||||||||||||||||
| (In millions, except per share amounts) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| Income from Continuing Operations | $ | 405 | $ | 344 | $ | 1,389 | $ | 1,258 | ||||||||||||||||||
| Less: Net income attributable to noncontrolling interests | (7) | (8) | (22) | (17) | ||||||||||||||||||||||
| Income from Continuing Operations Attributable to Kimberly-Clark Corporation | 398 | 336 | 1,367 | 1,241 | ||||||||||||||||||||||
| Income from Discontinued Operations, Net of Income Taxes | 1,395 | 110 | 1,436 | 281 | ||||||||||||||||||||||
| Net Income Attributable to Kimberly-Clark Corporation | $ | 1,793 | $ | 446 | $ | 2,803 | $ | 1,522 | ||||||||||||||||||
| Weighted-Average Common Shares | ||||||||||||||||||||||||||
| Basic | 332.6 | 331.8 | 332.3 | 331.9 | ||||||||||||||||||||||
| Dilutive effect of stock options and restricted share unit awards | 1.1 | 1.3 | 1.1 | 1.3 | ||||||||||||||||||||||
| Diluted | 333.7 | 333.1 | 333.4 | 333.2 | ||||||||||||||||||||||
| Basic: | ||||||||||||||||||||||||||
| Continuing operations | $ | 1.20 | $ | 1.01 | $ | 4.11 | $ | 3.74 | ||||||||||||||||||
| Discontinued operations | 4.19 | 0.33 | 4.33 | 0.85 | ||||||||||||||||||||||
| Basic Earnings per Share | $ | 5.39 | $ | 1.34 | $ | 8.44 | $ | 4.59 | ||||||||||||||||||
| Diluted: | ||||||||||||||||||||||||||
| Continuing operations | $ | 1.19 | $ | 1.01 | $ | 4.10 | $ | 3.73 | ||||||||||||||||||
| Discontinued operations | 4.18 | 0.33 | 4.31 | 0.84 | ||||||||||||||||||||||
| Diluted Earnings per Share | $ | 5.37 | $ | 1.34 | $ | 8.41 | $ | 4.57 |
We use the treasury stock method to calculate the dilutive effect of our outstanding stock-based awards. Options outstanding not included in the computation of diluted EPS because their exercise price was greater than the average market price of the common shares were 2.1 million and 2.3 million for the three and nine months ended September 30, 2026, respectively, and 1.9 million and 1.1 million for the three and nine months ended September 30, 2025, respectively. The number of common shares outstanding as of September 30, 2026 and 2025 was 332.6 million and 331.9 million, respectively.
Note 8. Stockholders' Equity
Net unrealized currency gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries, except those in highly inflationary economies, are recorded in Accumulated Other Comprehensive Income ("AOCI"). For these operations, changes in exchange rates generally do not affect cash flows; therefore, unrealized translation adjustments are recorded in AOCI rather than net income. Upon sale or substantially complete liquidation of any of these subsidiaries, the applicable unrealized translation adjustment would be removed from AOCI and reported as part of the gain or loss on the sale or liquidation. The change in unrealized translation for the nine months ended September 30, 2026 was primarily due to amounts reclassified as part of the substantial liquidation of certain subsidiaries as part of the IFP Transaction and the strengthening of the U.S. dollar versus various foreign currencies.
Also included in unrealized translation amounts are the effects of foreign exchange rate changes on intercompany balances of a long-term investment nature and transactions designated as hedges of net foreign investments.
The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows:
| Unrealized Translation | Defined Benefit Pension Plans | Other Postretirement Benefit Plans | Cash Flow Hedges | ||||||||||||||||||||||||||
| Balance as of December 31, 2024 | $ | (3,068) | $ | (775) | $ | 47 | $ | 30 | |||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications | 355 | (22) | 4 | (117) | |||||||||||||||||||||||||
| (Income) loss reclassified from AOCI | — | 25 | (a) | (3) | (a) | 26 | (b) | ||||||||||||||||||||||
| Net current period other comprehensive income (loss) | 355 | 3 | 1 | (91) | |||||||||||||||||||||||||
| Balance as of September 30, 2025 | $ | (2,713) | $ | (772) | $ | 48 | $ | (61) | |||||||||||||||||||||
| Balance as of December 31, 2025 | $ | (2,673) | $ | (758) | $ | 47 | $ | (60) | |||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications | (39) | 6 | 22 | 92 | |||||||||||||||||||||||||
| (Income) loss reclassified from AOCI | (310) | (c) | 24 | (a) | (4) | (a) | 46 | (b) | |||||||||||||||||||||
| Net current period other comprehensive income (loss) | (349) | 30 | 18 | 138 | |||||||||||||||||||||||||
| Balance as of September 30, 2026 | $ | (3,022) | $ | (728) | $ | 65 | $ | 78 |
(a) Included in Nonoperating expense as part of the computation of net periodic benefit costs.
(b) Included in Interest expense, Cost of products sold or Other (income) and expense, net, based on the income statement line that the hedged exposure affects earnings.
(c) Included in Other (income) and expense, net, as part of the gain recognized on the IFP Transaction during the third quarter of 2026 and reported within Income from Discontinued Operations, Net of Income Taxes (see Note 3).
Note 9. Objectives and Strategies for Using Derivatives
As a multinational enterprise, we are exposed to financial risks, such as changes in foreign currency exchange rates, interest rates, and commodity prices. We employ a number of practices to manage these risks, including operating and financing activities and, where appropriate, the use of derivative instruments.
As of September 30, 2026 and December 31, 2025, derivative assets were $235 and $81, respectively, and derivative liabilities were $215 and $191, respectively, primarily comprised of foreign currency exchange, interest rate and commodity price contracts. Derivative assets are recorded in Other current assets or Other Assets, as appropriate, and derivative liabilities are recorded in Accrued expenses and other current liabilities or Other Liabilities, as appropriate.
Foreign Currency Exchange Rate Risk
Translation adjustments result from translating foreign entities' financial statements into U.S. dollars from their functional currencies. The risk to any particular entity's net assets is reduced to the extent that the entity is financed with local currency borrowings. A portion of our balance sheet translation exposure for certain affiliates, which results from changes in translation rates between the affiliates’ functional currencies and the U.S. dollar, is hedged with cross-currency swap contracts and certain foreign denominated debt which are designated as net investment hedges. The foreign currency exposure on certain non-functional currency denominated monetary assets and liabilities, primarily intercompany loans and accounts payable, is hedged primarily with undesignated derivative instruments.
Derivative instruments are used to hedge a portion of forecasted cash flows denominated in foreign currencies for non-U.S. operations' purchases of raw materials, which are priced in U.S. dollars, and imports of intercompany finished goods and work-in-process inventories priced predominantly in U.S. dollars and euros. The derivative instruments used to manage these exposures are designated as cash flow hedges.
Interest Rate Risk
Interest rate risk is managed using a portfolio of variable and fixed-rate debt composed of short and long-term instruments. Interest rate swap contracts may be used to facilitate the maintenance of the desired ratio of variable and fixed-rate debt and are designated as fair value hedges. We also use derivative instruments, such as forward-starting swaps or treasury lock contracts, to manage our exposure to changes in benchmark interest rates associated with our anticipated issuance of fixed-rate debt. These derivative instruments are typically designated as cash flow hedges.
Commodity Price Risk
We use derivative instruments, such as commodity forward and price swap contracts, to hedge a portion of our exposure to market risk arising from changes in prices of certain commodities. These derivatives are primarily designated as cash flow hedges of specific quantities of the underlying commodity expected to be purchased in future months. In addition, we utilize negotiated contracts of varying durations along with strategic pricing mechanisms to manage volatility for a portion of our commodity costs. We also enter into undesignated commodity derivative contracts to economically hedge commodity price volatility for certain input and transportation costs.
Fair Value Hedges
Derivative instruments that are designated and qualify as fair value hedges are predominantly used to manage interest rate risk. The fair values of these derivative instruments are recorded as an asset or liability, as appropriate, with the offset recorded in Interest expense. The offset to the change in fair values of the related debt is also recorded in Interest expense. Any realized gain or loss on the derivatives that hedge interest rate risk is amortized to Interest expense over the life of the related debt. As of September 30, 2026, the aggregate notional values and carrying values of debt subject to outstanding interest rate contracts designated as fair value hedges were $300 and $275, respectively. For the three and nine months ended September 30, 2026 and 2025, gains or losses recognized in Interest expense for interest rate swaps were not material.
Cash Flow Hedges
For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative instrument is initially recorded in AOCI, net of related income taxes, and recognized in earnings in the same income statement line and period that the hedged exposure affects earnings.
Foreign Exchange and Commodity Contracts
As of September 30, 2026, the aggregate notional value of outstanding foreign exchange and commodity derivative contracts designated as cash flow hedges was $2.3 billion. The maximum maturity of foreign exchange and commodity derivative contracts in place as of September 30, 2026 is August 2029.
Unrealized losses of $42 and $9 were recorded in AOCI for the three months ended September 30, 2026 and 2025, respectively. Unrealized losses of $22 and $153 were recorded in AOCI for the nine months ended September 30, 2026 and 2025, respectively. Losses of $8 and $17 for the three months ended September 30, 2026 and 2025, respectively, and losses of $52 and $34 for the nine months ended September 30, 2026 and 2025, respectively, were reclassified from AOCI to Income from Discontinued Operations, Net of Income Taxes (discussed further below), Other (income) and expense, net and Cost of products sold.
For the three and nine months ended September 30, 2026, and the three months ended September 30, 2025, no material gains or losses were reclassified from AOCI into earnings as a result of the discontinuance of cash flow hedge accounting. For the nine months ended September 30, 2025, we discontinued cash flow hedge accounting for certain foreign exchange and commodity instruments with a notional value of $694 because the forecasted transactions were no longer probable of occurring due to the IFP Transaction. As a result, pre-tax losses of $20 were reclassified from AOCI into Income from Discontinued Operations, Net of Income Taxes.
Forward-Starting Interest Rate Swap Contracts
In the second quarter of 2026, we entered into $4.3 billion of aggregate notional forward-starting interest rate swaps in anticipation of the issuance of fixed-rate debt in connection with the Kenvue Acquisition. The gains or losses initially recorded in AOCI will be amortized and recorded in Interest expense over the term of the hedged debt. Unrealized gains of $183 and $159 were recorded in AOCI for the three and nine months ended September 30, 2026, respectively. Subsequent to September 30, 2026, we settled these instruments in connection with the issuance of senior unsecured notes to fund the Cash Consideration. See Note 12 for further information.
As of September 30, 2026, losses associated with our cash flow hedges expected to be reclassified from AOCI into Interest expense, Cost of products sold or Other (income) and expense, net during the next twelve months are $14.
Net Investment Hedges
For derivative instruments that are designated and qualify as net investment hedges, unrealized gains and losses related to changes in fair value of net investment hedges are recorded in AOCI and offset the change in the value of the net investment being hedged. As of September 30, 2026, the aggregate notional value of these instruments was
$1.8 billion. We exclude the interest accruals on cross-currency swap contracts and the forward points on foreign exchange forward contracts from the assessment and measurement of hedge effectiveness. Interest accruals on cross-currency swap contracts are recognized in earnings within Interest expense. We amortize the forward points on foreign exchange contracts into earnings within Interest expense over the life of the hedging relationship. Unrealized losses of $46 and gains of $29 were recorded in AOCI for the three months ended September 30, 2026 and 2025, respectively. Unrealized losses of $31 and $119 were recorded in AOCI for the nine months ended September 30, 2026 and 2025, respectively. For the three and nine months ended September 30, 2026 and 2025, no material amounts were reclassified from AOCI to Interest expense.
For the three and nine months ended September 30, 2026 and 2025, no material amounts were excluded from the assessment of net investment, fair value or cash flow hedge effectiveness.
Undesignated Hedging Instruments
Gains and losses on undesignated hedging instruments are immediately recognized in earnings as a component of Other (income) and expense, net, for our foreign exchange contracts and Cost of products sold for our commodity contracts. Losses of $7 and $10 were recorded for the three months ended September 30, 2026 and 2025, respectively. Losses of $10 and gains of $52 were recorded for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, the notional amount of these undesignated derivative instruments was approximately $4.3 billion.
Note 10. Segment Reporting
The Company's continuing operations are organized by operating segments aggregated into two reportable segments defined by geographic region: North America ("NA") and International Personal Care ("IPC").
The reportable segments were determined in accordance with how our Chief Executive Officer, who is our chief operating decision maker ("CODM"), develops and executes global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses. The primary measure of segment profitability utilized by our CODM is segment operating profit. Our CODM uses this measure to assess the operating results and performance of our segments, perform analytical comparisons to budget and allocate resources to each segment. Segment operating profit excludes Corporate & Other, which primarily encompasses certain unallocated general corporate expenses, impairment charges, one-time (gains) or losses associated with acquisitions and divestitures, costs related to our reorganization activities that are not associated with the ongoing operations of the segments, unrealized gains and losses on undesignated commodity hedges, which are initially recorded in Corporate & Other and reclassified to segment operating results when realized, certain operations of the former IFP segment that were divested prior to the IFP Transaction and costs previously allocated to the former IFP segment that aren't reported as discontinued operations. Our CODM does not use assets by segment to evaluate performance or allocate resources. Therefore, we do not disclose assets by segment.
The principal sources of revenue in each segment are described below:
-
North America** consists of products encompassing each of our five global daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. These products are sold under the Huggies, Pull-Ups, GoodNites, Kotex, Poise, Depend, Kleenex, Scott, Cottonelle, Viva, Wypall and other brand names.
-
International Personal Care** consists of three core categories — Baby & Child Care, Adult Care and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. These products are sold under the Huggies, Kotex, Goodfeel, Intimus, Depend and other brand names.
The tables below present net sales and the significant expense categories that are included in Segment Operating Profit and regularly provided to our CODM:
| Three Months Ended September 30, 2026 | ||||||||||||||||||||
| NA | IPC | Total | ||||||||||||||||||
| Net Sales | $ | 2,738 | $ | 1,396 | $ | 4,134 | ||||||||||||||
| Cost of Products Sold | 1,674 | 985 | 2,659 | |||||||||||||||||
| Advertising and Promotion Expense | 168 | 85 | 253 | |||||||||||||||||
| Research, Selling and General Expense | 239 | 180 | 419 | |||||||||||||||||
| Other (Income) and Expense, net(a) | — | 2 | 2 | |||||||||||||||||
| Segment Operating Profit | $ | 657 | $ | 144 | $ | 801 | ||||||||||||||
| Corporate & Other | (285) | |||||||||||||||||||
| Total Operating Profit | $ | 516 |
| Nine Months Ended September 30, 2026 | ||||||||||||||||||||
| NA | IPC | Total | ||||||||||||||||||
| Net Sales | $ | 8,087 | $ | 4,399 | $ | 12,486 | ||||||||||||||
| Cost of Products Sold | 4,791 | 2,980 | 7,771 | |||||||||||||||||
| Advertising and Promotion Expense | 534 | 297 | 831 | |||||||||||||||||
| Research, Selling and General Expense | 757 | 544 | 1,301 | |||||||||||||||||
| Other (Income) and Expense, net(a) | — | 3 | 3 | |||||||||||||||||
| Segment Operating Profit | $ | 2,005 | $ | 575 | $ | 2,580 | ||||||||||||||
| Corporate & Other | (678) | |||||||||||||||||||
| Total Operating Profit | $ | 1,902 |
| Three Months Ended September 30, 2025 | ||||||||||||||||||||
| NA | IPC | Total | ||||||||||||||||||
| Net Sales | $ | 2,714 | $ | 1,436 | $ | 4,150 | ||||||||||||||
| Cost of Products Sold | 1,655 | 957 | 2,612 | |||||||||||||||||
| Advertising and Promotion Expense | 184 | 90 | 274 | |||||||||||||||||
| Research, Selling and General Expense | 235 | 173 | 408 | |||||||||||||||||
| Other (Income) and Expense, net(a) | — | 2 | 2 | |||||||||||||||||
| Segment Operating Profit | $ | 640 | $ | 214 | $ | 854 | ||||||||||||||
| Corporate & Other | (233) | |||||||||||||||||||
| Total Operating Profit | $ | 621 |
(a) Other (income) and expense, net primarily includes the effects of changes in exchange rates on monetary assets and liabilities for subsidiaries where we have adopted highly inflationary accounting.
| Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| NA | IPC | Total | ||||||||||||||||||
| Net Sales | $ | 8,112 | $ | 4,255 | $ | 12,367 | ||||||||||||||
| Cost of Products Sold | 4,860 | 2,830 | 7,690 | |||||||||||||||||
| Advertising and Promotion Expense | 519 | 293 | 812 | |||||||||||||||||
| Research, Selling and General Expense | 760 | 529 | 1,289 | |||||||||||||||||
| Other (Income) and Expense, net(a) | — | 6 | 6 | |||||||||||||||||
| Segment Operating Profit | $ | 1,973 | $ | 597 | $ | 2,570 | ||||||||||||||
| Corporate & Other | (726) | |||||||||||||||||||
| Total Operating Profit | $ | 1,844 |
(a) Other (income) and expense, net primarily includes the effects of changes in exchange rates on monetary assets and liabilities for subsidiaries where we have adopted highly inflationary accounting.
Depreciation and amortization expense by segment:
| Three Months Ended September 30 | Nine Months Ended September 30 | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| NA | $ | 131 | $ | 115 | $ | 392 | $ | 343 | ||||||||||||||||||
| IPC | 53 | 61 | 152 | 196 | ||||||||||||||||||||||
| Total Segment Depreciation and Amortization | 184 | 176 | 544 | 539 | ||||||||||||||||||||||
| Corporate & Other | — | — | — | 9 | ||||||||||||||||||||||
| Total**(a)** | $ | 184 | $ | 176 | $ | 544 | $ | 548 |
(a) Excludes discontinued operations. See Note 3 for depreciation and amortization of discontinued operations.
Capital spending by segment:
| Three Months Ended September 30 | Nine Months Ended September 30 | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| NA | $ | 196 | $ | 181 | $ | 739 | $ | 465 | ||||||||||||||||||
| IPC | 32 | 36 | 123 | 107 | ||||||||||||||||||||||
| Total Segment Capital Spending | 228 | 217 | 862 | 572 | ||||||||||||||||||||||
| Corporate & Other | 35 | 96 | 96 | 96 | ||||||||||||||||||||||
| Total**(a)** | $ | 263 | $ | 313 | $ | 958 | $ | 668 |
(a) Excludes discontinued operations. See Note 3 for capital spending of discontinued operations.
Sales of Principal Products:
| Three Months Ended September 30 | Nine Months Ended September 30 | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Baby and Child Care | $ | 1,599 | $ | 1,685 | $ | 5,047 | $ | 5,090 | ||||||||||||||||||
| Family Care | 1,066 | 1,036 | 3,121 | 3,060 | ||||||||||||||||||||||
| Professional | 482 | 474 | 1,418 | 1,385 | ||||||||||||||||||||||
| Adult Care | 512 | 490 | 1,488 | 1,458 | ||||||||||||||||||||||
| Feminine Care | 433 | 431 | 1,307 | 1,286 | ||||||||||||||||||||||
| All other | 42 | 34 | 105 | 88 | ||||||||||||||||||||||
| Total | $ | 4,134 | $ | 4,150 | $ | 12,486 | $ | 12,367 |
Note 11. Supplemental Balance Sheet Data
The following schedule presents a summary of inventories by major class:
| September 30, 2026 | December 31, 2025 | |||||||||||||||||||||||||||||||||||||
| LIFO | Non-LIFO | Total | LIFO | Non-LIFO | Total | |||||||||||||||||||||||||||||||||
| Raw materials | $ | 115 | $ | 237 | $ | 352 | $ | 114 | $ | 197 | $ | 311 | ||||||||||||||||||||||||||
| Work in process | 113 | 39 | 152 | 111 | 38 | 149 | ||||||||||||||||||||||||||||||||
| Finished goods | 536 | 494 | 1,030 | 484 | 468 | 952 | ||||||||||||||||||||||||||||||||
| Supplies and other | — | 253 | 253 | — | 254 | 254 | ||||||||||||||||||||||||||||||||
| 764 | 1,023 | 1,787 | 709 | 957 | 1,666 | |||||||||||||||||||||||||||||||||
| Excess of FIFO or weighted-average cost over LIFO cost | (208) | — | (208) | (191) | — | (191) | ||||||||||||||||||||||||||||||||
| Total | $ | 556 | $ | 1,023 | $ | 1,579 | $ | 518 | $ | 957 | $ | 1,475 |
Inventories are valued at the lower of cost or net realizable value, determined on the FIFO or weighted-average cost methods, and at the lower of cost or market, determined on the LIFO cost method.
The following schedule presents a summary of property, plant and equipment, net:
| September 30, 2026 | December 31, 2025 | |||||||||||||
| Land | $ | 145 | $ | 134 | ||||||||||
| Buildings | 2,650 | 2,354 | ||||||||||||
| Machinery and equipment | 13,088 | 12,820 | ||||||||||||
| Construction in progress | 1,274 | 1,201 | ||||||||||||
| 17,157 | 16,509 | |||||||||||||
| Less accumulated depreciation | (10,090) | (9,734) | ||||||||||||
| Total | $ | 7,067 | $ | 6,775 |
Supplier Finance Program
We have a supplier finance program managed through two global financial institutions under which we agree to pay the financial institutions the stated amount of confirmed invoices from our participating suppliers on the invoice due date. We, or the global financial institutions, may terminate our agreements at any time upon 30 days written notice. The global financial institutions may terminate our agreements at any time upon three days written notice in the event there are insufficient funds available for disbursement. We do not provide any forms of guarantees under these agreements. Supplier participation in the program is solely up to the supplier, and the participating suppliers negotiate their arrangements directly with the global financial institutions. We have no economic interest in a supplier’s decision to participate in the program, and their participation has no bearing on our payment terms or amounts due. The payment terms that we have with our suppliers under this program generally range from 75 to 180 days and are considered commercially reasonable. The outstanding amount related to the suppliers participating in this program was $836 and $1.1 billion as of September 30, 2026 and December 31, 2025, respectively. The balance as of December 31, 2025 included $184 reported within discontinued operations. Amounts are recorded within Trade accounts payable and Current liabilities of discontinued operations.
Note 12. Subsequent Events
Senior Notes Offering
On October 29, 2026, we completed a private offering (the "Offering") of senior unsecured notes (the "Notes") in an aggregate principal amount of $4.9 billion. The Notes consist of $750 of 5.10% Notes due 2028, $1.0 billion of 5.30% Notes due 2029, $1.25 billion of 5.45% Notes due 2031, $750 of 5.65% Notes due 2034 and $1.15 billion of 5.80% Notes due 2036. We used the net proceeds from the Offering, together with cash on hand and borrowings under our commercial paper program of approximately $1.0 billion, to fund the Cash Consideration and related fees and expenses of the Kenvue Acquisition.
Kenvue Integration Program
On October 30, 2026, in connection with the Kenvue Acquisition, our Board of Directors approved the Kenvue Integration Program (the "Program") which is intended to achieve certain operating profit synergies by 2030. Actions contemplated under the Program commenced on November 2, 2026 and are expected to be completed by
December 31, 2029. The Program is expected to result in cumulative pre-tax charges of approximately $3.1 billion ($2.5 billion cash and $0.6 billion non-cash) over this period, with cash charges primarily related to supply chain network optimization (approximately $800), enterprise resource planning and technology integration (approximately $600), workforce optimization (approximately $400), advisory services (approximately $400) and program management and other restructuring and integration costs (approximately $300). Non-cash charges are primarily related to supply chain network optimization.
Kenvue Acquisition
On November 2, 2026, we completed the Kenvue Acquisition for Cash Consideration of approximately $6.7 billion. In respect of the Kenvue common stock issued and outstanding immediately prior to the effective time of the Kenvue Acquisition, we have delivered or caused to be delivered approximately 281.1 million shares of K-C common stock to Kenvue shareholders. The acquisition will be accounted for as a business combination under ASC 805, Business Combinations. Given the close proximity between the transaction closing date and the filing of this Quarterly Report on Form 10-Q, the preliminary purchase price allocation is not yet complete. The initial accounting for this acquisition, including the determination of the estimated fair value of converted Kenvue equity awards attributable to pre-combination service and the purchase price allocation, will be provided in our Annual Report on Form 10-K for the year ending December 31, 2026. Kenvue's results will be included in our consolidated financial statements from the acquisition date.
In connection with the Kenvue Acquisition, on November 4, 2026, we completed the previously announced exchange offers and consent solicitations for Kenvue's $7.0 billion aggregate principal amount of outstanding senior notes (the "Kenvue Notes"). Holders of Kenvue Notes validly tendered approximately $6.4 billion, or approximately 91.1%, of the Kenvue Notes and, on November 4, 2026, we issued a like-amount of new senior notes. The aggregate principal amount of Kenvue Notes that remained outstanding following the settlement of the exchange offers was approximately $0.6 billion and will be reflected in our consolidated total debt following the acquisition.
Previous: Cover and table of contents · Next: Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations